Sponsor

Ludwig Institute for Cancer Research

Clinical research sponsor

Published trials14
Recruiting shown2
Roles2
SourceClinicalTrials.gov

Clinical trials

14 shown
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCNCT03164772 · lead sponsor · 2017-12-20
COMPLETED
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerNCT02898116 · lead sponsor · 2017-05-10
COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersNCT02643303 · lead sponsor · 2016-12-28
COMPLETED
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantNCT02716805 · lead sponsor · 2016-12-13
TERMINATED
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerNCT02735239 · lead sponsor · 2016-06-24
COMPLETED
A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabNCT01975831 · lead sponsor · 2013-12-19
COMPLETED
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung CancerNCT01266018 · lead sponsor · 2011-01-01
TERMINATED
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 AntigenNCT00623831 · lead sponsor · 2007-05-01
COMPLETED
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing CancersNCT00291473 · lead sponsor · 2005-07-01
COMPLETED
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate CancerNCT00292045 · lead sponsor · 2004-10-27
COMPLETED
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer VaccineNCT00199849 · lead sponsor · 2004-09-27
COMPLETED
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)NCT00084799 · lead sponsor · 2004-07-26
COMPLETED
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast CancerNCT05736367 · collaborator · 2024-11-15
RECRUITING
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · collaborator · 2024-10-30
RECRUITING

Sponsor roles

lead sponsor12
collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.